Related Experiment Videos
A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma
1Geraldine Brush Cancer Research Institute, California Pacific Medical Center, San Francisco 94115, USA.
Abstract:
A novel human gene CC3 with properties of a metastasis suppresor gene for small cell lung carcinoma (SCLC) is described. CC3 is an evolutionary conserved gene that is expressed ubiquitously in human tissues. CC3 RNA is absent in a subset of SCLC cell lines known as variant (v-SCLC) that are derived from tumors characterized by highly aggressive metastatic behavior. Introduction of CC3 into a variant SCLC line results in significant suppression of its metastasis in vivo. When deprived of growth factors in vitro, v-SCLC cells modified to express CC3 undergo rapid and massive cell death that at least partially could be ascribed to the activation of the apoptotic pathway. In addition, expression of CC3 in v-SCLC cells increases induction of apoptosis by chemoterapeutic drugs. Loss of CC3 in highly metastatic cells such as SCLC might render them resistant to death-inducing signals and thus help to ensure their survival under unfavorable conditions encountered in the metastatic process.
Insights
A novel gene, CC3, acts as a metastasis suppressor for small cell lung carcinoma (SCLC). Restoring CC3 in aggressive SCLC cells inhibits metastasis and promotes cell death, offering new therapeutic avenues.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell lung carcinoma (SCLC) is an aggressive cancer with a high metastatic potential.
- A subset of SCLC, known as variant SCLC (v-SCLC), exhibits particularly aggressive metastatic behavior.
- The molecular mechanisms underlying SCLC metastasis and the potential for metastasis suppressor genes are not fully understood.
Purpose of the Study:
- To identify and characterize novel genes involved in the suppression of SCLC metastasis.
- To investigate the role of the newly identified gene, CC3, in SCLC progression and metastasis.
- To explore the therapeutic potential of CC3 in combating SCLC metastasis and enhancing treatment efficacy.
Main Methods:
- Gene expression analysis of CC3 in various human tissues and SCLC cell lines.
- Introduction of CC3 into v-SCLC cell lines to assess its effect on metastatic potential in vivo.
- In vitro studies to evaluate the impact of CC3 expression on cell death and apoptosis induction under growth factor deprivation and chemotherapy.
- Analysis of the apoptotic pathway activation in response to CC3 expression.
Main Results:
- CC3 is a ubiquitously expressed, evolutionarily conserved human gene.
- CC3 RNA is notably absent in aggressive v-SCLC cell lines.
- Introduction of CC3 into v-SCLC cells significantly suppressed their metastatic capabilities in vivo.
- CC3 expression in v-SCLC cells induced rapid cell death upon growth factor deprivation, partly via apoptosis.
- CC3 expression enhanced apoptosis induction by chemotherapeutic drugs in v-SCLC cells.
Conclusions:
- CC3 functions as a metastasis suppressor gene for small cell lung carcinoma.
- Loss of CC3 may contribute to the aggressive metastatic phenotype of v-SCLC by conferring resistance to cell death.
- Restoring CC3 expression holds promise as a therapeutic strategy to inhibit SCLC metastasis and improve treatment outcomes.